A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is application/pdf
.
Excessive Biologic Response to IFNβ Is Associated with Poor Treatment Response in Patients with Multiple Sclerosis
2011
PLoS ONE
Interferon-beta (IFNb) is used to inhibit disease activity in multiple sclerosis (MS), but its mechanisms of action are incompletely understood, individual treatment response varies, and biological markers predicting response to treatment have yet to be identified. Methods: The relationship between the molecular response to IFNb and treatment response was determined in 85 patients using a longitudinal design in which treatment effect was categorized by brain magnetic resonance imaging as good
doi:10.1371/journal.pone.0019262
pmid:21602934
pmcid:PMC3094352
fatcat:xgko7femdrhzbpvdemj625k5z4